Scroll to top
- Follow Us
- –

̍̍ CSE: BRAX
̍̍ OTC: BRAXF
̍̍ FWB: 4960

©2022 Braxia Scientific Corp.

DISCLAIMER — The information on this site should not be used to make decisions about medical treatments. Please conduct your own research and due diligence before making any major health changes. Braxia Scientific, its members, directors, employees, and representatives are not responsible for damages of any nature arising out of or relating to the use of this website or any hyperlinked websites. The material that appears on this website is for informational purposes only. Braxia Scientific has made every effort to provide useful and accurate information. However, errors may appear from time to time. Braxia Scientific and its information providers make no warranty as to the reliability, timeliness, completeness, accuracy or usefulness of the information on the website. Any opinion, view, or idea contained in an article, story or column published on this website is that of the author and does not reflect or represent the views of Braxia Scientific or any of its members, directors, employees and representatives.

Go back

3 min read

CHANGES AT THE TOP

Published on November 24, 2020

Home
News Releases
CHANGES AT THE TOP

CHAMPIGNON BRANDS UPDATES INVESTORS ON CHANGES AT THE TOP

VANCOUVER, BRITISH COLUMBIA (November 24, 2020) – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced today that the Company’s management and governance is undergoing comprehensive change at the top that will extend to the Company’s practices.

In today’s update the Company announces a series of moves now underway as a basis for emphasized priorities on transparency, full and accurate public reporting plus operational readiness to meet the accelerating, pandemic-drive demand for its clinical services.

In this light, the Company reminds investors it is now led by a new Board Chair and CEO and new Vice-Chair, both announced previously (see news release dated October 5, 2020). Other changes underway include the following:

The Company is now actively recruiting a new Chief Financial Officer, Chief General Counsel, and Senior Vice President – Investor and Public Communications.
The Company intends to expand its board with additional outside directors to be drawn from business and science.
The Company has accepted the resignation of Gareth Birdsall, director, effective November 23, 2020.
The Company has re-designed its website to facilitate proper access to current information by investors and the wider public.

The current Board of Directors consists of Dr. Roger McIntyre, Chair and CEO; Bill Wilkerson, Vice-Chair; Matt Fish, President and Secretary; and Jerry Habuda.

Champignon Brands Inc. (http://braxiascientific.com) is a research-driven Company specializing in breakthrough ketamine treatment for depression, and other mental health conditions and its suicidal implications as well as delivery platforms for other health products. The Company works closely with subsidiaries that include AltMed Capital Corp. (“AltMed”), Novo Formulations Ltd., Artisan Growers Ltd., and Tassili Life Sciences Corp. The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.

Investors: [email protected]

Media: Victoria Ollers, [email protected], 416 822-2288

Symbols – CSE: BRAX OTC: BRAXF FWB: 496

Next Post

OPENS SECOND LOCATION

News Releases

Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic

Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure. TORONTO, ONTARIO Monday June 12, 2023 – Braxia Scientific Corp. (“Braxia”, or the“Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with mentalhealth clinics providing innovative ketamine and psilocybin treatments for depression and relateddisorders, is pleased to report treatment volumes across its clinics increased 26.2% to 3,516 from2,785 treatments on a year-over-year basis in Fiscal 2023. The Company continues to experienceincreased demand across all of it 5 clinics. At its new Ottawa clinic, treatment volumes increased87.2% to 571 from 305 treatments on a year-over-year basis following the completion of constructionand opening of its expanded purpose-built clinic in late 2022. Additionally, its Kitchener-Waterlooclinic, opened in mid-2022, continues to see rapid increases in treatment volume, reaching 214treatments in its first 8 months of operation.“Over...

News Releases

Braxia Scientific Reports Fiscal 2023 Financial Results

Braxia Health ketamine treatments up 26% YoY in 2023 and revenue up 27% YoY Company completes dosing of final participant in Phase 2, multi-dose Psilocybin trial, results expected to be published prior to end of 2023 Company reviewing financing options, strategic partnerships and further cost reductions and organizational changes as required TORONTO, ONTARIO July 31, 2023 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and twelve months ended March 31, 2023. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for...